Company: Sanofi
Posted by DupixentSE_SNY · March 22, 2026
Tags: territory, pipeline
Dupixent access for atopic dermatitis in commercial lives is genuinely strong right now.
Medicare Part D is still more complicated but we've gotten better processes.
The challenge is the growing number of patients on Rinvoq or Cibinqo who switched from Dupixent — that's real and it's happening.
Not because Dupixent failed but because JAK inhibitor reps are doing a better job at re-engaging lapsed patients.
I think Dupixent's advantage in safety profile is still meaningful for a lot of patients and prescribers, especially in pediatrics.
But we can't coast.
The IL-4/IL-13 message alone isn't enough anymore — you need the nuanced safety data conversation.
27 upvotes · 0 comments